成人隐匿性自身免疫糖尿病可能代表自身免疫性(1型)与非自身免疫性(2型)糖尿病的混合人群
成人隐匿性自身免疫糖尿病(LADA)通常定义为35岁后新诊断、具有2型糖尿病临床特征但检出1型糖尿病相关胰岛自身抗体的糖尿病。文章指出,现有LADA定义所识别的人群在临床和遗传特征上介于典型1型和2型糖尿病之间,这主要源于在低患病率人群中用特异性不完美的胰岛自身抗体检测来定义LADA,导致真阳性(自身免疫性1型糖尿病)和假阳性(非自身免疫性2型糖尿病)混合。对临床医生而言,无自身免疫糖尿病临床特征的患者不应进行胰岛自身抗体检测;对研究者而言,当前LADA定义不适合研究晚发自身免疫糖尿病。
要点
- LADA定义依赖胰岛自身抗体检测,在低患病率人群中特异性不足,易混入假阳性的2型糖尿病。
- 无1型糖尿病临床特征的成人,单次胰岛自身抗体阳性很可能是假阳性,不应常规检测。
- 当前LADA定义不适合用于晚发自身免疫糖尿病的研究,需提高检测特异性或预先概率。
核心结论
- LADA可能代表自身免疫性(1型)和非自身免疫性(2型)糖尿病的混合人群,分类困难是主要成分。
研究设计与样本
- 本文为综述/观点文章,未报告系统检索范围或样本量。
主要发现
- 现有LADA定义识别的人群临床和遗传特征介于典型1型和2型糖尿病之间。
- 在低患病率人群中用特异性不完美的胰岛自身抗体检测定义LADA,会产生真阳性和假阳性混合。
- 无1型糖尿病临床特征的成人单次抗体阳性很可能是假阳性,而有1型糖尿病特征者假阳性罕见。
关键数值与推荐
- LADA通常定义为35岁后新诊断糖尿病、具有2型糖尿病临床特征且检出1型糖尿病相关胰岛自身抗体。
- 无自身免疫糖尿病临床特征的患者不应进行胰岛自身抗体检测。
临床怎么用
- 临床医生应仅对具有提示自身免疫糖尿病临床特征的患者进行胰岛自身抗体检测。
- 无1型糖尿病临床特征的成人,不应仅凭单次抗体阳性诊断自身免疫糖尿病。
局限性
- 本文为观点/综述,未提供原始研究数据或系统评价。
- 未报告提高检测特异性或预先概率的具体方法或阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Latent autoimmune diabetes of adults (LADA) is typically defined as a new diabetes diagnosis after 35 years of age, presenting with clinical features of type 2 diabetes, in whom a type 1 diabetes-associated islet autoantibody is detected. Identifying autoimmune diabetes is important since the prognosis and optimal therapy differ. However, the existing LADA definition identifies a group with clinical and genetic features intermediate between typical type 1 and type 2 diabetes. It is unclear whether this is due to 1) true autoimmune diabetes with a milder phenotype at older onset ages that initially appears similar to type 2 diabetes but later requires insulin, 2) a disease syndrome where the pathophysiologies of type 1 and type 2 diabetes are both present in each patient, or 3) a heterogeneous group resulting from difficulties in classification. Herein, we suggest that difficulties in classification are a major component resulting from defining LADA using a diagnostic test-islet autoantibody measurement-with imperfect specificity applied in low-prevalence populations. This yields a heterogeneous group of true positives (autoimmune type 1 diabetes) and false positives (nonautoimmune type 2 diabetes). For clinicians, this means that islet autoantibody testing should not be undertaken in patients who do not have clinical features suggestive of autoimmune diabetes: in an adult without clinical features of type 1 diabetes, it is likely that a single positive antibody will represent a false-positive result. This is in contrast to patients with features suggestive of type 1 diabetes, where false-positive results will be rare. For researchers, this means that current definitions of LADA are not appropriate for the study of autoimmune diabetes in later life. Approaches that increase test specificity, or prior likelihood of autoimmune diabetes, are needed to avoid inclusion of participants who have nonautoimmune (type 2) diabetes. Improved classification will allow improved assignment of prognosis and therapy as well as an improved cohort in which to analyze and better understand the detailed pathophysiological components acting at onset and during disease progression in late-onset autoimmune diabetes.
引用
- Jones AG, McDonald TJ, Shields BM, et al. Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care. 2021. PMID: 34016607. doi:10.2337/dc20-2834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。